Merrimack Pharmaceuticals, Inc. (MACK)
| Market Cap | 223.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 200.46M |
| Shares Out | 14.79M |
| EPS (ttm) | 13.87 |
| PE Ratio | 1.09 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,255,765 |
| Open | 15.15 |
| Previous Close | 15.13 |
| Day's Range | 15.13 - 15.17 |
| 52-Week Range | 11.53 - 15.89 |
| Beta | 1.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2024 |
About MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. [Read more]
Financial Performance
Financial StatementsNews
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) announced that the stockholders at a Special Meeting held today overwhelmingly approved...
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt.
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has filed notice with NASDAQ of the Company's intent to delist ...
Merrimack Receives $225 Million Milestone Payment from Ipsen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced that it has received a $225 million payment which was due from Ipsen, S...
Merrimack Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2023 Financial Results.
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) reported that Ipsen, SA (“Ipsen”) issued a press release today announcing the U.S. Food...
Merrimack Reports Third Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Third Quarter 2023 Financial Results.
Merrimack Reports Second Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2023 Financial Results.
Merrimack College Teacher Survey Highlights Troubling K-12 Teacher Morale Issues
NORTH ANDOVER, Mass.--(BUSINESS WIRE)--A newly released study shines a spotlight on a pressing crisis facing American education: Only 46% of current public K-12 educators would be “fairly” or “very li...
Merrimack Reports First Quarter 2023 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2023 financial results for the period ended March 3...
Merrimack Reports Full Year 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2022 financial results for the period ended December 31, ...
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has extended the Section 3...
Merrimack stock rockets 200% after positive trial data on Onivyde pancreatic cancer treatment
Shares of Merrimack Pharmaceuticals Inc. MACK, +224.14% skyrocketed 199.5% toward a 4 1/2-year high in morning trading Wednesday, after the France-based biopharmaceutical company Ipsen IPSEY, +1.39% I...
Merrimack Reports Second Quarter 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2022 Financial Results
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Provides Ipsen report of results from Phase III RESILIENT trial evaluating Onivyde® in second-line monotherapy for small cell lung cancer
Merrimack Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 3...
Merrimack Reports Full Year 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2021 Financial Results
Merrimack Reports Third Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Reports Third Quarter 2021 Financial Results
Merrimack Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, ...
Merrimack Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Full Year 2020 Financial Results
Merrimack Reports Third Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Pharmaceuticals Q3 2020 Earnings Release
Merrimack Reports Second Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merrimack Reports Second Quarter 2020 Financial Results